Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Current Assets (2021 - 2025)

Historic Current Assets for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $353.4 million.

  • Amylyx Pharmaceuticals' Current Assets rose 4408.33% to $353.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $353.4 million, marking a year-over-year increase of 4408.33%. This contributed to the annual value of $189.4 million for FY2024, which is 5923.27% down from last year.
  • Amylyx Pharmaceuticals' Current Assets amounted to $353.4 million in Q3 2025, which was up 4408.33% from $186.9 million recorded in Q2 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Current Assets peaked at $464.7 million during Q4 2023, and registered a low of $105.0 million during Q4 2021.
  • Over the past 5 years, Amylyx Pharmaceuticals' median Current Assets value was $296.1 million (recorded in 2022), while the average stood at $299.0 million.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Current Assets soared by 26410.61% in 2022 and then tumbled by 5923.27% in 2024.
  • Amylyx Pharmaceuticals' Current Assets (Quarter) stood at $105.0 million in 2021, then surged by 264.11% to $382.1 million in 2022, then grew by 21.6% to $464.7 million in 2023, then plummeted by 59.23% to $189.4 million in 2024, then soared by 86.55% to $353.4 million in 2025.
  • Its Current Assets stands at $353.4 million for Q3 2025, versus $186.9 million for Q2 2025 and $216.1 million for Q1 2025.